# Moderna

> Moderna is a VC fund in Cambridge backing Biotechnology and Health Care. See 5 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 5
- Last investment: Mar 2023
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/moderna-/
- X (Twitter): http://twitter.com/moderna_tx
- Website: http://www.modernatx.com
- Facebook: http://www.facebook.com/modernatx

Moderna is a VC fund in Cambridge focused on Biotechnology and Health Care. Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies insidepatient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

## Contacts

5 contacts available for Moderna. Shizune tracks 8 team members at Moderna. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/moderna-therapeutics?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Health Care | 2 | 40% |
| Genetics | 1 | 20% |
| Hedge Funds | 1 | 20% |
| Therapeutics | 1 | 20% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 20% |
| Funding Round | 1 | 20% |
| Debt Financing | 1 | 20% |
| Post-IPO Equity | 1 | 20% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Eric Ma | Principal Data Scientist | 0 | https://shizune.co/investors/profile/eric-ma-e39a |
| Kenneth Chien | Co-Founder | 2 | https://shizune.co/investors/profile/kenneth-chien |
| Marcello Damiani | Chief Digital & Operational Excellence Officer | 0 | https://shizune.co/investors/profile/marcello-damiani |
| John Mendlein | President, Corporate and Product Strategy | 0 | https://shizune.co/investors/profile/john-mendlein |
| Noubar Afeyan | Chairman & Co-Founder | 31 | https://shizune.co/investors/profile/noubar-afeyan |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Generation Bio | Generation Bio is an innovative genetic medicines company focused on creating a new class of gene therapy to provide durable, redosable treatments for patients suffering from both rare and prevalent diseases. The company’s non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novelcell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company is designing therapies to provide targeted delivery of genetic payloads that include large and multiple genes across a broad array of tissues, and to be redosable for individualized and extended treatment throughout a patient’s life. The platform is designed to expand access to treatments for rare diseases and to address prevalent diseases through efficient, scalable manufacturing. | $76M | Post-IPO Equity | Mar 23, 2023 |  |
| Metagenomi | Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems. | $100M | Series B | Jan 05, 2023 |  |
| Metagenomi | Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems. | $175M | Series B | Jan 25, 2022 |  |
| Leightal Capital Management | Leightal Capital Management is a global hedge fund that invests in a variety of asset classes, including equities, fixed income, and commodities. The fund is managed by a team of experienced professionals with a proven track record of success. Leightal Capital Management is committed to providing its investors with superior returns over the longterm. The fund's investment philosophy is based on the belief that alpha can be generated by identifying and investing in mispriced assets. The fund's investment team uses a variety of research and analysis techniques to identify mispriced assets. The team also has a strong focus on risk management and capital preservation. Leightal Capital Management is a good choice for investors who are looking for a long-term investment partner with a proven track record of success. | $5.5M | Debt Financing | Jan 01, 2022 |  |
| Onkaido Therapeutics | The Onkaido Therapeutics team is exploring how messenger RNA therapeutics™ can deliver novel oncology drugs to help patients. | $20M |  | Jan 14, 2014 |  |

5 of 5 investments shown.

## Co-investors
- [Farallon Capital Management](https://shizune.co/investors/profile/farallon-capital-management) — VC Fund, 2 deals together
- [Leaps by Bayer](https://shizune.co/investors/profile/leaps-by-bayer) — VC Fund, 2 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 2 deals together
- [PFM Health Sciences](https://shizune.co/investors/profile/pfm-health-sciences) — VC Fund, 2 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 2 deals together
- [BlackRock](https://shizune.co/investors/profile/blackrock) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Moderna invest in?

Moderna invests primarily in Biotechnology, Health Care and Genetics startups, most often at Series B and Funding Round stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Moderna?

Public channels for Moderna include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Moderna?

The team at Moderna includes Eric Ma (Principal Data Scientist), Kenneth Chien (Co-Founder) and Marcello Damiani (Chief Digital & Operational Excellence Officer), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co